Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048997 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase 3 study of Lung Cancer, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 356
- Enrollment target
- 14
- Study locations
NCT00048997 is a Phase 3 study of Lung Cancer that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 356 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (62% lower). The trial reports 14 study locations across 10 states.
The verdict
NCT00048997, a Phase 3 study of Lung Cancer, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 356 participants
- Enrollment target
- 14
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if giving radiation therapy to the head is effective in preventing CNS metastases in patients who have stage III non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying how well radiation therapy to the head works in preventing CNS metastases in patients who have been previously treated for stage III non-small cell lung cancer.
Conditions Studied
Interventions
- OTHER Observation
- RADIATION Radiation therapy
Study Locations (14)
Arizona
- Arizona Oncology Services Foundation - Phoenix
- Virginia G. Piper Cancer Center at Scottsdale Healthcare - Osborn - Scottsdale
- Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea - Scottsdale
Maine
- Central Maine Comprehensive Cancer Center at Central Maine Medical Center - Lewiston
- Maine Center for Cancer Medicine and Blood Disorders - Scarborough - Scarborough
Pennsylvania
- Geisinger Cancer Institute at Geisinger Health - Danville
- Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center - Wilkes-Barre
Illinois
- Resurrection Medical Center - Chicago
Maryland
- Shore Regional Cancer Center at Memorial Hospital - Easton - Easton
Massachusetts
- MetroWest Medical Center - Framingham Union Hospital - Framingham
Michigan
- Josephine Ford Cancer Center at Henry Ford Hospital - Detroit
New Jersey
- Cancer Institute of New Jersey at Cooper University Hospital - Camden - Camden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 356 participants |
| Start Date | 2002-09 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048997
The ClinicalTrials.gov registry entry for NCT00048997 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 356 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (62% lower). The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Observation is the first listed.
NCT00048997 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Arizona, Maine, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00048997 about?
NCT00048997 is a clinical study titled "Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if giving radiation therapy to the head is effective in preventing CNS metastases in patients who have stage III non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying how well ...
What is the current status of trial NCT00048997?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 356 participants. The study started on 2002-09. Estimated completion is 2016-12.
What conditions does trial NCT00048997 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00048997?
The interventions under investigation include: Observation (OTHER), Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00048997?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00048997 being conducted?
This trial has 14 study locations across Arizona, Illinois, Maine, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.